PAR-25-269-Full-Announcement.html

This Notice of Funding Opportunity (NOFO) announces the NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (PAR-25-269), administered by the Department of Health and Human Services National Institutes of Health under CFDA 93.213. The funding opportunity supports investigator-initiated early phase clinical trials of natural products, including botanicals, probiotics, dietary supplements, and standardized nutritional regimens containing specific naturally occurring compounds.

The award uses a phased R61/R33 mechanism, with up to three years of initial R61 support for milestone-driven testing of pharmacokinetics, bioavailability, and mechanism of action assessment, followed by up to three additional years of R33 support if milestones are met. The R33 phase focuses on replicating target engagement impacts and examining associations with clinical outcomes, including optimization of product delivery through different doses or formulations. Eligible applicants include state and local governments, higher education institutions, tribal organizations, nonprofits, small businesses, and other organizations. The program falls under Research and Training in Complementary and Integrative Health (93.213), which aims to evaluate complementary and integrative health approaches through peer-reviewed grants.